Home › Research › How common it is
Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort
Luís E. Santos, Paulo Mattos, TC Pinheiro, Ananssa Silva, Cláudia Drummond, Felipe Kenji Sudo, Fernanda G. Q. Barros‐Aragão, Bart Vanderborght et al.. Nature Communications, 2025-03-25
Topic: Risk, prevention and care in population studies
Plain-language summary
Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (n = 49), amnestic mild cognitive impairment (n = 29), AD (n = 38), Lewy body dementia (n = 22), or vascular dementia (n = 7). Plasma Tau, Aβ40, Aβ42, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ42 (ROC AUC = 0.98, 95% CI: [0.94–1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil. Plasma biomarkers of Alzheimer’s disease and dementia are remarkable tools but still lack validation in Low and Middle-Income Countries. In this longitudinal study, authors report on the plasma biomarker profile of a Brazilian dementia cohort.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 49 participants. In this small Brazilian cohort of 145 elderly participants, plasma pTau217 showed excellent performance in determining CSF biomarker status, alone or as a ratio to Aβ42. Reported effect size: AUC = 0.94; AUC = 0.98.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Santos, L. E., Mattos, P., Pinheiro, T. C., Silva, A., Drummond, C., Sudo, F. K., et al. (2025). Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort. Nature Communications. https://doi.org/10.1038/s41467-025-56756-3
Vancouver
Santos LE, Mattos P, Pinheiro TC, Silva A, Drummond C, Sudo FK, et al. Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort. Nature Communications. 2025. doi:10.1038/s41467-025-56756-3. PMID: 40133253.
BibTeX
@article{santos2025-40133253,
author = {Santos, Luís E. and Mattos, Paulo and Pinheiro, TC and Silva, Ananssa and Drummond, Cláudia and Sudo, Felipe Kenji and Barros‐Aragão, Fernanda G. Q. and Vanderborght, Bart and others},
title = {{Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort}},
journal = {Nature Communications},
year = {2025},
doi = {10.1038/s41467-025-56756-3},
pmid = {40133253},
url = {https://doi.org/10.1038/s41467-025-56756-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma Tau, Aβ40, Aβ42, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform.
- Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ42 (ROC AUC = 0.98, 95% CI: [0.94–1.00]).
- This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil.
- Plasma biomarkers of Alzheimer’s disease and dementia are remarkable tools but still lack validation in Low and Middle-Income Countries.
- In this longitudinal study, authors report on the plasma biomarker profile of a Brazilian dementia cohort.
Why it matters
In this small Brazilian cohort of 145 elderly participants, plasma pTau217 showed excellent performance in determining CSF biomarker status, alone or as a ratio to Aβ42. The authors describe this as an initial step toward local validation and adoption of dementia biomarkers in Brazil.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designcohort study
- Participants49
- Effect sizeAUC = 0.94; AUC = 0.98
- Evidence strengthModerate
How this study scored 66/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Communications) |
| Journal's citation record | 4 / 4 | Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 49 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 23 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 14.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Fernanda G. De Felice: h-index 66 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Queen's University: institution h-index 794 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40133253) |
| Free to read | 2 / 2 | Free to read |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41467-025-56756-3
- PubMed: 40133253
- Original source →
- Free full text: Nature Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in How common it is from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.